Reaction Details |
| Report a problem with these data |
Target | Urokinase-type plasminogen activator |
---|
Ligand | BDBM50153004 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_1564079 (CHEMBL3783220) |
---|
Ki | >29730±n/a nM |
---|
Citation | Corte, JR; Fang, T; Pinto, DJ; Orwat, MJ; Rendina, AR; Luettgen, JM; Rossi, KA; Wei, A; Ramamurthy, V; Myers, JE; Sheriff, S; Narayanan, R; Harper, TW; Zheng, JJ; Li, YX; Seiffert, DA; Wexler, RR; Quan, ML Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group. Bioorg Med Chem24:2257-72 (2016) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Urokinase-type plasminogen activator |
---|
Name: | Urokinase-type plasminogen activator |
Synonyms: | 3.4.21.73 | PLAU | U-plasminogen activator | UROK_HUMAN | Urokinase | Urokinase-type plasminogen activator (uPA) | Urokinase-type plasminogen activator chain B | Urokinase-type plasminogen activator long chain A | Urokinase-type plasminogen activator short chain A | Urokinase-type plasminogen activator/surface receptor | uPA |
Type: | Enzyme |
Mol. Mass.: | 48528.62 |
Organism: | Homo sapiens (Human) |
Description: | P00749 |
Residue: | 431 |
Sequence: | MRALLARLLLCVLVVSDSKGSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQ
HCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHN
YCRNPDNRRRPWCYVQVGLKLLVQECMVHDCADGKKPSSPPEELKFQCGQKTLRPRFKII
GGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLG
RSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICL
PSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKML
CAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIR
SHTKEENGLAL
|
|
|
BDBM50153004 |
---|
n/a |
---|
Name | BDBM50153004 |
Synonyms: | CHEMBL3781319 |
Type | Small organic molecule |
Emp. Form. | C31H26ClN7O3 |
Mol. Mass. | 580.036 |
SMILES | COC(=O)Nc1ccc(cc1)-c1ccnc(c1)[C@H](Cc1ccccc1)NC(=O)\C=C\c1cc(Cl)ccc1-n1cnnn1 |r| |
Structure |
|